Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Prospective randomized phase-II trial with Temsirolimus versus Sunitinib in previously untreated patients with advanced or metastatic non-clear cell renal carcinoma

    Summary
    EudraCT number
    2009-010143-13
    Trial protocol
    DE  
    Global end of trial date
    02 Jul 2016

    Results information
    Results version number
    v1(current)
    This version publication date
    05 Sep 2020
    First version publication date
    05 Sep 2020
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    C-II-006
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    CESAR Central European Society for Anticancer Drug Research-EWIV
    Sponsor organisation address
    Hangluessgasse 4/1-3, Vienna, Austria, 1150
    Public contact
    Prof. Viktor Grünwald, Medizinische Hochschule Hannover, 0049 5115323140, gruenwald.viktor@mh-hannover.de
    Scientific contact
    Dr. Max Roessler, CESAR Central European Society for Anticancer Drug Research-EWIV, 0043 1522 30 9316, max.roessler@cesar.or.at
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    30 Nov 2016
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    02 Jul 2016
    Global end of trial reached?
    Yes
    Global end of trial date
    02 Jul 2016
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    Primary objective of the study is to demonstrate a statistical significant difference between the two arms in progression free survival (PFS) measured from randomisation until progression or death, whichever occurs first.
    Protection of trial subjects
    All drugs used in the study were used according to the technical information. Procedures that determine efficacy (CT scans, MRI) and safety (blood count, blood chemistry and coagulation) are performed as in routine operations and therefore do not represent an additional burden for those patients participating in this clinical trial. Blood samples taken outside the routine for the accompanying programs do not pose any additional risk to patients. In summary, it is not possible to predict whether there will be a direct benefit for the individual patients. However, the risk for patients in the study is not higher than for patients not treated in the study. Furthermore, there is a benefit for future patients due to the progress of knowledge. It can be concluded that the benefit of this research project outweighs the risks involved.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    09 Jul 2009
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Germany: 22
    Worldwide total number of subjects
    22
    EEA total number of subjects
    22
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    14
    From 65 to 84 years
    7
    85 years and over
    1

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    17 study sites in Germany were activated for patient recruitment. Only 10 of the study sites actively recruited patients into the study. Patient recruitment took place from 09Jul2009 (FPI) to 27Aug2015 (LPLV).

    Pre-assignment
    Screening details
    The screening criteria were defined by the inclusion and exclusion criteria as defined in the study protocol.

    Period 1
    Period 1 title
    Treatment Phase (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Arm A
    Arm description
    Temsirolimus is supplies in vials containing 30 mg of temsirolimus-concentrate (1.2 ml) together with a diluent (2.2 ml). When diluted, the solution contains 10 mg/ml. Temsirolimus is administered on days 1, 8, 15, 22, 29, 36 of each treatment cycle (cycle duration is 6 weeks). The recommended dose of temsirolimus for advanced renal cell carcinoma administered intravenously is 25 mg infused over a 30- to 60-minute period once weekly. Patients must be given intravenous diphenhydramine 25 to 50 mg (or similar antihistamine) approximately 30 minutes before the start of each dose of temsirolimus. Treatment is continued until disease progression.
    Arm type
    Experimental

    Investigational medicinal product name
    Temsirolimus
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate and solvent for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Temsirolimus is supplies in vials containing 30 mg of temsirolimus-concentrate (1.2 ml) together with a diluent (2.2 ml). When diluted, the solution contains 10 mg/ml. Temsirolimus is administered on days 1, 8, 15, 22, 29, 36 of each treatment cycle (cycle duration is 6 weeks). The recommended dose of temsirolimus for advanced renal cell carcinoma administered intravenously is 25 mg infused over a 30- to 60-minute period once weekly. Patients must be given intravenous diphenhydramine 25 to 50 mg (or similar antihistamine) approximately 30 minutes before the start of each dose of temsirolimus. Treatment is continued until disease progression.

    Arm title
    Arm B
    Arm description
    Sunitinib is available as hard capsules in 3 different strengths: 12.5 mg, 25 mf and 50 mg. 50 mg Sunitinib was administered orally on days 1-28 of each treatment cycle, followed by 2 weeks (days 29-42) of treatment pause (duration of treatment cycles 6 weeks). Treatment was continued until disease progression.
    Arm type
    Experimental

    Investigational medicinal product name
    Sunitinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, hard
    Routes of administration
    Oral use
    Dosage and administration details
    Sunitinib is available as hard capsules in 3 different strengths: 12.5 mg, 25 mf and 50 mg. 50 mg Sunitinib was administered orally on days 1-28 of each treatment cycle, followed by 2 weeks (days 29-42) of treatment pause (duration of treatment cycles 6 weeks). Treatment was continued until disease progression.

    Number of subjects in period 1
    Arm A Arm B
    Started
    12
    10
    Completed
    12
    10

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Arm A
    Reporting group description
    Temsirolimus is supplies in vials containing 30 mg of temsirolimus-concentrate (1.2 ml) together with a diluent (2.2 ml). When diluted, the solution contains 10 mg/ml. Temsirolimus is administered on days 1, 8, 15, 22, 29, 36 of each treatment cycle (cycle duration is 6 weeks). The recommended dose of temsirolimus for advanced renal cell carcinoma administered intravenously is 25 mg infused over a 30- to 60-minute period once weekly. Patients must be given intravenous diphenhydramine 25 to 50 mg (or similar antihistamine) approximately 30 minutes before the start of each dose of temsirolimus. Treatment is continued until disease progression.

    Reporting group title
    Arm B
    Reporting group description
    Sunitinib is available as hard capsules in 3 different strengths: 12.5 mg, 25 mf and 50 mg. 50 mg Sunitinib was administered orally on days 1-28 of each treatment cycle, followed by 2 weeks (days 29-42) of treatment pause (duration of treatment cycles 6 weeks). Treatment was continued until disease progression.

    Reporting group values
    Arm A Arm B Total
    Number of subjects
    12 10 22
    Age categorical
    Units: Subjects
        In utero
    0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0
        Newborns (0-27 days)
    0 0 0
        Infants and toddlers (28 days-23 months)
    0 0 0
        Children (2-11 years)
    0 0 0
        Adolescents (12-17 years)
    0 0 0
        Adults (18-64 years)
    9 5 14
        From 65-84 years
    2 5 7
        85 years and over
    1 0 1
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    57.4 ( 14.8 ) 64.8 ( 11.8 ) -
    Gender categorical
    Units: Subjects
        Female
    4 2 6
        Male
    8 8 16
    Subject analysis sets

    Subject analysis set title
    Arm A
    Subject analysis set type
    Intention-to-treat
    Subject analysis set description
    Patients which have been randomized in Arm A of the study.

    Subject analysis set title
    Arm B
    Subject analysis set type
    Intention-to-treat
    Subject analysis set description
    Patient which have been randomized in Arm B of the study.

    Subject analysis sets values
    Arm A Arm B
    Number of subjects
    12
    10
    Age categorical
    Units: Subjects
        In utero
    0
    0
        Preterm newborn infants (gestational age < 37 wks)
    0
    0
        Newborns (0-27 days)
    0
    0
        Infants and toddlers (28 days-23 months)
    0
    0
        Children (2-11 years)
    0
    0
        Adolescents (12-17 years)
    0
    0
        Adults (18-64 years)
    9
    5
        From 65-84 years
    2
    5
        85 years and over
    1
    0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    57.4 ( 14.8 )
    64.8 ( 11.8 )
    Gender categorical
    Units: Subjects
        Female
    4
    2
        Male
    8
    8

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Arm A
    Reporting group description
    Temsirolimus is supplies in vials containing 30 mg of temsirolimus-concentrate (1.2 ml) together with a diluent (2.2 ml). When diluted, the solution contains 10 mg/ml. Temsirolimus is administered on days 1, 8, 15, 22, 29, 36 of each treatment cycle (cycle duration is 6 weeks). The recommended dose of temsirolimus for advanced renal cell carcinoma administered intravenously is 25 mg infused over a 30- to 60-minute period once weekly. Patients must be given intravenous diphenhydramine 25 to 50 mg (or similar antihistamine) approximately 30 minutes before the start of each dose of temsirolimus. Treatment is continued until disease progression.

    Reporting group title
    Arm B
    Reporting group description
    Sunitinib is available as hard capsules in 3 different strengths: 12.5 mg, 25 mf and 50 mg. 50 mg Sunitinib was administered orally on days 1-28 of each treatment cycle, followed by 2 weeks (days 29-42) of treatment pause (duration of treatment cycles 6 weeks). Treatment was continued until disease progression.

    Subject analysis set title
    Arm A
    Subject analysis set type
    Intention-to-treat
    Subject analysis set description
    Patients which have been randomized in Arm A of the study.

    Subject analysis set title
    Arm B
    Subject analysis set type
    Intention-to-treat
    Subject analysis set description
    Patient which have been randomized in Arm B of the study.

    Primary: Primary Endpoint

    Close Top of page
    End point title
    Primary Endpoint [1]
    End point description
    End point type
    Primary
    End point timeframe
    Date of first diagnosis until progressiv disease
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The study has been terminated prematurely due to poor recruitment. The statistical analysis as planned in the study protocol was not done. Instead a descriptive analysis was performed.
    End point values
    Arm A Arm B Arm A Arm B
    Number of subjects analysed
    12
    10
    12
    10
    Units: Months
        median (confidence interval 95%)
    9.3 (1.6 to 15.9)
    13.2 (1.9 to 15.9)
    9.3 (1.6 to 15.9)
    13.2 (1.9 to 15.9)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    All information on AEs and SAEs will be reported during the treatment phase up to 4 weeks after the end of the treatment phase. Any SAEs beyond 28 days after the last dose of study medication considered related to the study medication will be reported.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    20.0
    Reporting groups
    Reporting group title
    Arm A
    Reporting group description
    Temsirolimus is supplies in vials containing 30 mg of temsirolimus-concentrate (1.2 ml) together with a diluent (2.2 ml). When diluted, the solution contains 10 mg/ml. Temsirolimus is administered on days 1, 8, 15, 22, 29, 36 of each treatment cycle (cycle duration is 6 weeks). The recommended dose of temsirolimus for advanced renal cell carcinoma administered intravenously is 25 mg infused over a 30- to 60-minute period once weekly. Patients must be given intravenous diphenhydramine 25 to 50 mg (or similar antihistamine) approximately 30 minutes before the start of each dose of temsirolimus. Treatment is continued until disease progression.

    Reporting group title
    Arm B
    Reporting group description
    Sunitinib is available as hard capsules in 3 different strengths: 12.5 mg, 25 mf and 50 mg. 50 mg Sunitinib was administered orally on days 1-28 of each treatment cycle, followed by 2 weeks (days 29-42) of treatment pause (duration of treatment cycles 6 weeks). Treatment was continued until disease progression.

    Serious adverse events
    Arm A Arm B
    Total subjects affected by serious adverse events
         subjects affected / exposed
    7 / 12 (58.33%)
    6 / 10 (60.00%)
         number of deaths (all causes)
    7
    5
         number of deaths resulting from adverse events
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Metastases to peritoneum
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Vascular disorders
    Lymphoedema
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Surgical and medical procedures
    Lymphadenectomy
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Chest pain
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Disease progression
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Fatigue
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General physical health deterioration
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    local swelling
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    multi-organ failure
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Pulmonary embolism
         subjects affected / exposed
    1 / 12 (8.33%)
    1 / 10 (10.00%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Investigations
    Electrocardiogram QT prolonged
         subjects affected / exposed
    0 / 12 (0.00%)
    2 / 10 (20.00%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    Hemiparesis
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Posterior reversible encephalopathy syndrome
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Anemia
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Leukopenia
         subjects affected / exposed
    0 / 12 (0.00%)
    2 / 10 (20.00%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Thrombocytopenia
         subjects affected / exposed
    0 / 12 (0.00%)
    2 / 10 (20.00%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haematuria
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal failure
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Abscess neck
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Arthritis infective
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Hypokalaemia
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hyponatraemia
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    Arm A Arm B
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    11 / 12 (91.67%)
    10 / 10 (100.00%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Acrochordon
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Tumour pain
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Vascular disorders
    Flushing
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Haematoma
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Hot flush
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Hypertension
         subjects affected / exposed
    2 / 12 (16.67%)
    2 / 10 (20.00%)
         occurrences all number
    2
    3
    Hypotension
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Lymphoedema
         subjects affected / exposed
    1 / 12 (8.33%)
    1 / 10 (10.00%)
         occurrences all number
    1
    1
    General disorders and administration site conditions
    Chest discomfort
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Chest pain
         subjects affected / exposed
    2 / 12 (16.67%)
    0 / 10 (0.00%)
         occurrences all number
    2
    0
    Chills
         subjects affected / exposed
    2 / 12 (16.67%)
    1 / 10 (10.00%)
         occurrences all number
    2
    2
    Fatigue
         subjects affected / exposed
    2 / 12 (16.67%)
    5 / 10 (50.00%)
         occurrences all number
    4
    12
    Feeling cold
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    local swelling
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Mucosal inflammation
         subjects affected / exposed
    4 / 12 (33.33%)
    4 / 10 (40.00%)
         occurrences all number
    4
    5
    Oedema
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Oedema peripheral
         subjects affected / exposed
    3 / 12 (25.00%)
    0 / 10 (0.00%)
         occurrences all number
    3
    0
    Pain
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Peripheral swelling
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    2
    0
    Pyrexia
         subjects affected / exposed
    3 / 12 (25.00%)
    1 / 10 (10.00%)
         occurrences all number
    25
    1
    Immune system disorders
    Hypersensitivity
         subjects affected / exposed
    1 / 12 (8.33%)
    1 / 10 (10.00%)
         occurrences all number
    1
    1
    Oral herpes
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Reproductive system and breast disorders
    Benign prostatic hyperplasia
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Pelvic pain
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    vaginal inflammation
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    2
    0
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    2 / 12 (16.67%)
    0 / 10 (0.00%)
         occurrences all number
    2
    0
    Dysphonia
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Dyspnoea
         subjects affected / exposed
    4 / 12 (33.33%)
    0 / 10 (0.00%)
         occurrences all number
    4
    0
    Epistaxis
         subjects affected / exposed
    1 / 12 (8.33%)
    2 / 10 (20.00%)
         occurrences all number
    1
    2
    Haemoptysis
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    2
    0
    Oropharyngeal pain
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    2
    0
    Pleural effusion
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    2
    0
    Pleurisy
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Psychiatric disorders
    Depression
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Insomnia
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Sleep disorder
         subjects affected / exposed
    2 / 12 (16.67%)
    0 / 10 (0.00%)
         occurrences all number
    3
    0
    Tension
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    3
    0
    Aspartate aminotransferase increased
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    2
    0
    Blood cholesterol increased
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    6
    0
    Blood lactate dehydrogenase increased
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    2
    0
    C-reactive protein increased
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Haemoglobin decreased
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Low density lipoprotein increased
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    4
    0
    Weight decreased
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    2
    Weight increased
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Injury, poisoning and procedural complications
    Wound
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Nervous system disorders
    Ageusia
         subjects affected / exposed
    0 / 12 (0.00%)
    2 / 10 (20.00%)
         occurrences all number
    0
    5
    Dizziness
         subjects affected / exposed
    1 / 12 (8.33%)
    1 / 10 (10.00%)
         occurrences all number
    1
    1
    Dysgeusia
         subjects affected / exposed
    4 / 12 (33.33%)
    3 / 10 (30.00%)
         occurrences all number
    4
    3
    Headache
         subjects affected / exposed
    2 / 12 (16.67%)
    2 / 10 (20.00%)
         occurrences all number
    3
    2
    Intercostal neuralgia
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Neuropathy peripheral
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Paraesthesia
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Blood and lymphatic system disorders
    anemia
         subjects affected / exposed
    1 / 12 (8.33%)
    1 / 10 (10.00%)
         occurrences all number
    1
    1
    Leukopenia
         subjects affected / exposed
    0 / 12 (0.00%)
    3 / 10 (30.00%)
         occurrences all number
    0
    5
    neutopenia
         subjects affected / exposed
    0 / 12 (0.00%)
    2 / 10 (20.00%)
         occurrences all number
    0
    2
    Thrombocytopenia
         subjects affected / exposed
    0 / 12 (0.00%)
    3 / 10 (30.00%)
         occurrences all number
    0
    6
    Ear and labyrinth disorders
    Inner ear inflammation
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    2
    0
    Middle ear effusion
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Vertigo
         subjects affected / exposed
    1 / 12 (8.33%)
    1 / 10 (10.00%)
         occurrences all number
    2
    1
    Eye disorders
    Dry eye
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Eye oedema
         subjects affected / exposed
    1 / 12 (8.33%)
    2 / 10 (20.00%)
         occurrences all number
    1
    2
    Gastrointestinal disorders
    Abdominal discomfort
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Abdominal pain
         subjects affected / exposed
    5 / 12 (41.67%)
    1 / 10 (10.00%)
         occurrences all number
    9
    2
    Abdominal pain upper
         subjects affected / exposed
    3 / 12 (25.00%)
    1 / 10 (10.00%)
         occurrences all number
    3
    1
    Cheilitis
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Constipation
         subjects affected / exposed
    3 / 12 (25.00%)
    1 / 10 (10.00%)
         occurrences all number
    4
    1
    Diarrhoea
         subjects affected / exposed
    3 / 12 (25.00%)
    2 / 10 (20.00%)
         occurrences all number
    3
    4
    Dry mouth
         subjects affected / exposed
    1 / 12 (8.33%)
    1 / 10 (10.00%)
         occurrences all number
    1
    1
    Dyspepsia
         subjects affected / exposed
    1 / 12 (8.33%)
    5 / 10 (50.00%)
         occurrences all number
    1
    10
    Dysphagia
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Epigastric discomfort
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Flatulence
         subjects affected / exposed
    1 / 12 (8.33%)
    1 / 10 (10.00%)
         occurrences all number
    1
    2
    Gastritis
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    2
    0
    Haemorrhoids
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Mouth ulceration
         subjects affected / exposed
    2 / 12 (16.67%)
    0 / 10 (0.00%)
         occurrences all number
    2
    0
    Nausea
         subjects affected / exposed
    3 / 12 (25.00%)
    5 / 10 (50.00%)
         occurrences all number
    6
    11
    Oral pain
         subjects affected / exposed
    2 / 12 (16.67%)
    1 / 10 (10.00%)
         occurrences all number
    2
    1
    Stomatitis
         subjects affected / exposed
    4 / 12 (33.33%)
    3 / 10 (30.00%)
         occurrences all number
    7
    3
    Tongue discolouration
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Vomiting
         subjects affected / exposed
    2 / 12 (16.67%)
    3 / 10 (30.00%)
         occurrences all number
    2
    4
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    3
    0
    Hepatobiliary disorders
    Jaundice
         subjects affected / exposed
    0 / 12 (0.00%)
    2 / 10 (20.00%)
         occurrences all number
    0
    3
    Skin and subcutaneous tissue disorders
    Acne
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Alopecia
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Dry skin
         subjects affected / exposed
    1 / 12 (8.33%)
    2 / 10 (20.00%)
         occurrences all number
    1
    2
    Erythema
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Hair colour changes
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Hyperhidrosis
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Nail disorder
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Night sweats
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Onychoclasis
         subjects affected / exposed
    2 / 12 (16.67%)
    0 / 10 (0.00%)
         occurrences all number
    2
    0
    Palmar-plantar erythrodysaesthesia syndrome
         subjects affected / exposed
    1 / 12 (8.33%)
    3 / 10 (30.00%)
         occurrences all number
    1
    4
    Pruritus
         subjects affected / exposed
    5 / 12 (41.67%)
    0 / 10 (0.00%)
         occurrences all number
    6
    0
    Rash
         subjects affected / exposed
    6 / 12 (50.00%)
    1 / 10 (10.00%)
         occurrences all number
    9
    1
    Skin erosion
         subjects affected / exposed
    1 / 12 (8.33%)
    1 / 10 (10.00%)
         occurrences all number
    1
    2
    Skin fissures
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Skin lesion
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Xeroderma
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Yellow skin
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    5
    Renal and urinary disorders
    Bladder irritation
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Renal failure
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    2
    Back pain
         subjects affected / exposed
    2 / 12 (16.67%)
    1 / 10 (10.00%)
         occurrences all number
    3
    1
    Bone pain
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Flank pain
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Intervertebral disc protrusion
         subjects affected / exposed
    2 / 12 (16.67%)
    0 / 10 (0.00%)
         occurrences all number
    2
    0
    monarthritis
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Musculoskeletal chest pain
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    3
    0
    Musculoskeletal pain
         subjects affected / exposed
    2 / 12 (16.67%)
    1 / 10 (10.00%)
         occurrences all number
    2
    1
    Musculoskeletal stiffness
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Myalgia
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Myofascial pain syndrome
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Neck pain
         subjects affected / exposed
    2 / 12 (16.67%)
    0 / 10 (0.00%)
         occurrences all number
    4
    0
    Osteoarthritis
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    2
    0
    Pain in extremity
         subjects affected / exposed
    1 / 12 (8.33%)
    1 / 10 (10.00%)
         occurrences all number
    3
    1
    Spinal pain
         subjects affected / exposed
    3 / 12 (25.00%)
    0 / 10 (0.00%)
         occurrences all number
    5
    0
    Infections and infestations
    Abscess oral
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Tonsillitis
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Anal fungal infection
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    2
    Bronchitis
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Folliculitis
         subjects affected / exposed
    2 / 12 (16.67%)
    0 / 10 (0.00%)
         occurrences all number
    4
    0
    Fungal infection
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Furuncle
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Genital herpes zoster
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Gingivitis
         subjects affected / exposed
    1 / 12 (8.33%)
    1 / 10 (10.00%)
         occurrences all number
    1
    1
    Herpes zoster
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Laryngitis
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Mastoiditis
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Nasopharyngitis
         subjects affected / exposed
    2 / 12 (16.67%)
    1 / 10 (10.00%)
         occurrences all number
    5
    1
    Oesophageal candidiasis
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    Oral candidiasis
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Rhinitis
         subjects affected / exposed
    2 / 12 (16.67%)
    0 / 10 (0.00%)
         occurrences all number
    2
    0
    Upper respiratory tract infection
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Urinary tract infection
         subjects affected / exposed
    2 / 12 (16.67%)
    1 / 10 (10.00%)
         occurrences all number
    2
    1
    Viral upper respiratory tract infection
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Vulvovaginal candidiasis
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Metabolism and nutrition disorders
    Cachexia
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Decreased appetite
         subjects affected / exposed
    4 / 12 (33.33%)
    3 / 10 (30.00%)
         occurrences all number
    5
    8
    Hypercholesterolaemia
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    2
    0
    Hyperglycaemia
         subjects affected / exposed
    1 / 12 (8.33%)
    1 / 10 (10.00%)
         occurrences all number
    1
    1
    Hyperlipidaemia
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    1
    0
    Hypertriglyceridaemia
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 10 (0.00%)
         occurrences all number
    6
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    29 Mar 2010
    In a new product information for Sunitinib fistula formation was included as a potential adverse event. This was incorporated into the study protocol and informed consent.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 09:29:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA